First-Line Switch to B/F/TAF for Treatment of HIV in Older Adults ≥60 Years in Kenya (the B/F/TAF-Elderly Study) - Takeaways - MDSpire

First-Line Switch to B/F/TAF for Treatment of HIV in Older Adults ≥60 Years in Kenya (the B/F/TAF-Elderly Study)

  • By

  • Loice Achieng Ombajo

  • Jeremy Penner

  • Joseph Nkuranga

  • Victor Omodi

  • Edwin Otieno

  • Jared Ongechi Mecha

  • Simon Wahome

  • Florentius Ndinya

  • Rukia Aksam

  • Sanjay Bhagani

  • Rose Wafula

  • Anton Pozniak

  • Diana Nyakoe

  • On behalf of

  • the B/F/TAF-Elderly Study Group

  • Ruth Wanjohi

  • Arnold Onyango

  • Foram Bhogayata

  • Janet Oyoo

  • Susan Onywera

  • Martha Atandi

  • Agatha Theuri

  • Beryl Handa

  • Elizabeth Kamau

  • Susan Wanjiru

  • Eunice Karuoya

  • Amos Ongubo

  • Gerald Kiambi

  • Sheila Eshiwani Juliet

  • Lillian Gekonge

  • Florence Kinyanjui

  • Betty Chepchumba

  • Alex Morwabe

  • Kevin Wauna

  • Felix Hinga

  • November 20, 2025

  • 0 min

Share

  • 1

    The B/F/TAF-Elderly Trial evaluated switching to bictegravir/emtricitabine/tenofovir alafenamide in HIV-positive adults aged 60 and above in Kenya.

  • 2

    At week 48, the B/F/TAF group showed non-inferior HIV-1 RNA suppression compared to the current antiretroviral regimen, with 1.9% vs. 2.7% of participants having viral loads ≥50 copies/mL.

  • 3

    Participants switching to B/F/TAF experienced a significant increase in lumbar spine bone mineral density (BMD) compared to those continuing their current regimen.

  • 4

    Adverse events were similar between the two groups, but more participants on B/F/TAF developed dyslipidemia compared to those on the current regimen.

  • 5

    The trial highlights the potential benefits of switching to B/F/TAF for older adults with HIV, particularly regarding bone health and viral suppression.

Original Source(s)

First-Line Switch to B/F/TAF for Treatment of HIV in Older Adults ≥60 Years in Kenya (the B/F/TAF-Elderly Study)

  • by Loice Achieng Ombajo, Jeremy Penner, Joseph Nkuranga, Victor Omodi, Edwin Otieno, Jared Ongechi Mecha, Simon Wahome, Florentius Ndinya, Rukia Aksam, Sanjay Bhagani, Rose Wafula, Anton Pozniak, Diana Nyakoe, On behalf of, the B/F/TAF-Elderly Study Group, Ruth Wanjohi, Arnold Onyango, Foram Bhogayata, Janet Oyoo, Susan Onywera, Martha Atandi, Agatha Theuri, Beryl Handa, Elizabeth Kamau, Susan Wanjiru, Eunice Karuoya, Amos Ongubo, Gerald Kiambi, Sheila Eshiwani Juliet, Lillian Gekonge, Florence Kinyanjui, Betty Chepchumba, Alex Morwabe, Kevin Wauna, Felix Hinga

  • November 20, 2025

Related Content

How Language Shapes Care 

ACP examines ethical implications of calling all physicians “providers”

Comparing the Effectiveness of High Intensity Interval Training vs Continuous Moderate Intensity Exercise on Physical Function Among Older Adults With HIV

Influenza Vaccine Dose and Dementia Outcomes

US claims data compare high- vs standard-dose formulations in patients aged 65 years or more over 3 years of follow-up